Floatz logo

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Vascular Dementia

Peking University First HospitalSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Vascular Dementia cohort.

Asset / SponsorPhaseRating
PITTSBURGH COMPOUND B UNLABELLED
National Taiwan University Hospital
Phase 4BB
Risperdal
Janssen-Cilag Pty Ltd
Phase 3BB
Acetylsalicylic Acid
Peking University First Hospital
Phase 4BB
OXYCODONE HYDROCHLORIDE, HYDROCODONE-
VA Office of Research and Development
Phase 4BB
Rivastigmine
Novartis
Phase 3BB

View all 42 →

Same molecule, other indications

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:

cerebral infarctionDormant
BBB
Indicative ·
79 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
75 / 100
View asset →
ischemic strokeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →